The aim of this study is to evaluate the efficacy, adverse reactions, nutritional status analysis, and quality of life analysis of Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3 in the treatment of locally advanced nasopharyngeal carcinoma.
Written informed consent can be provided, and understanding and compliance with research requirements and evaluation schedules are required.
On the date of signing the informed consent form, the age range is between 18 and 65 years old (or the legal age specified by local laws).
Pathological diagnosis is non keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated, i.e. WHO classification II or III).
Clinical staging is anyTN2-3M0 or T4N1M0 (AJCC8th/UICC staging).
Nasopharyngeal cancer patients with recurrence and distant metastasis.
Pathology shows keratinized squamous cell carcinoma (WHO classification type I).
Patients who have undergone radiotherapy or systemic chemotherapy before.
Pregnant or lactating women who are in the reproductive period and have not taken effective contraceptive measures.